In the Journals

Long-term use of bisphosphonates after nerve-sparing surgery reduced recurrence of sacral giant cell tumors

Investigators found bisphosphonate used after nerve-sparing surgery for sacral giant cell tumors is an effective option.

Researchers evaluated 35 consecutive patients with sacral giant cell tumors. Of these patients, 19 received bisphosphonates after nerve-sparing surgery performed between January 2007 and December 2010 and 16 patients underwent nerve-sparing surgery alone before January 2007. Treatment groups were compared and the Kaplan-Meier method was used to estimate the postoperative recurrence of free-survival rates and overall survival rates.

Results showed good nerve function in all patients. The local recurrence rates in patients treated with bisphosphonates and those treated with nerve-sparing surgery alone were 10.53% and 43.75%, respectively. Patients treated with bisphosphonates compared with those who were not had a significantly higher 3-year recurrence-free survival and 3-year overall survival, according to results from the log-rank test. – by Monica Jaramillo

Disclosure: The researchers report no relevant financial disclosures.

Investigators found bisphosphonate used after nerve-sparing surgery for sacral giant cell tumors is an effective option.

Researchers evaluated 35 consecutive patients with sacral giant cell tumors. Of these patients, 19 received bisphosphonates after nerve-sparing surgery performed between January 2007 and December 2010 and 16 patients underwent nerve-sparing surgery alone before January 2007. Treatment groups were compared and the Kaplan-Meier method was used to estimate the postoperative recurrence of free-survival rates and overall survival rates.

Results showed good nerve function in all patients. The local recurrence rates in patients treated with bisphosphonates and those treated with nerve-sparing surgery alone were 10.53% and 43.75%, respectively. Patients treated with bisphosphonates compared with those who were not had a significantly higher 3-year recurrence-free survival and 3-year overall survival, according to results from the log-rank test. – by Monica Jaramillo

Disclosure: The researchers report no relevant financial disclosures.